Ko te GC203 he rongoā TIL hou kāore i te huaketo kua whakarerekētia e te ira, i whakawhanakehia mā te whakamahi i te tūāpapa whakawhānui pūtau DeepTIL® a Juncell Therapeutics me te tūāpapa whakarerekē ira NovaGMP®. Ka taea e DeepTIL® te kaha o ngā TIL kia kore ai e hiahiatia he huinga IL-2 i muri i te werohanga, ā, ka iti ake te kaha o te maimoatanga i mua. Ka whakarerekē a NovaGMP® i ngā pūtau-T me te tino whai huatanga e rite ana ki te ira Lentiviral i roto i te huarahi ōhanga. Kua hangaia a GC203 me te interleukin-7 e herea ana ki te kiriuhi, ka taea te pupuri i te pakari o ngā pūtau-T mahara, te whakahohe i ngā pūtau ārai mate ā-roto me te karo i ngā paitini pūnaha.
I whakamātauhia e ngā kairangahau a GC203 ki ngā tūroro i kitea he mate pukupuku ovarian e hokihoki ana, me te kore e whakamahia te whakakotahitanga o te whakahaere IL-2, te lymphodepletion kaha rānei. Ko te whāinga o te rangahau he whakatau i te haumaru me te whai huatanga o tēnei maimoatanga. E 20 ngā tūroro katoa i whakaurua i waenga i te 09/2021 me te 01/2024 i roto i te whakamātautau pokapū kotahi tuwhera, i reira 18 ngā tūroro i taea te aromatawai. Ko ngā tūroro i taea te aromatawai he ECOG PS o te 1 (55.6%), 2 rānei (44.4%), ā, i whiwhi i te toharite o te 5 ngā maimoatanga pūnaha o mua (awhe: 2-11). 9 (50%) ngā tūroro he 3, neke atu rānei ngā whara pukupuku. Ko te rahi toharite o te whara whāinga he 57 (awhe: 13-146) mm.
I whakaatuhia e te GC203 ngā hua whakamīharo i roto i ngā tūroro e pāngia ana e te mate pukupuku ovarian e hokihoki ana, e horapa ana rānei. I tino pai ake te āhua haumaru i whakaritea ki ngā maimoatanga TIL tuku iho, nā te iti o te kaha o te maimoatanga i mua me te whakakorenga o te huinga IL-2. Ko te nuinga o ngā Pānga Kino (AE) he taumata 1, he taumata 2 rānei, ā, ka taea te whakaiti, te whakaora rānei mā te maimoatanga tohumate. Kāore i puta he pānga taumata 5. I te rā kati o te 01/2024, ko te Reiti Urupare Whāinga (ORR) i aromatawaihia e te kairangahau he 33.3% (95% CI: 16.3 – 56.3), tae atu ki te 11.1% Urupare Katoa (CR). Ko te Reiti Whakahaere Mate (DCR) he 83.3% (95% CI, 60.8 – 94.2). Ā, ko te reiti Ora Whānui (OS) 12-marama he 68.8% (95% CI: 49.3 – 95.9). Kāore i pakeke te OS waenga i te wā kati raraunga.
I te tau 2023, i whakaurua a Whaea H ki te hōhipera nā te whara o tōna hope.me te mamae o te hopeI te tirotiro, i kitea he maha ngā pona lymph kua whakanuia i roto i te retroperitoneum, te hope, me ētahi atu wāhi, ā, e whakaū ana i tana mate pukupuku ovarian serous teitei. Nō reira, i tukuna a Ms. H ki te chemotherapy, ki te pokanga, ki te immunotherapy, me ētahi atu, engari kāore i tino pai te pānga, ā, ka hoki mai anō te pukupuku.
Nō reira, i whai wāhi atu a Ms. H ki te whakamātautau haumanu o te rongoā pūtau TIL GC203, ā, i muri i te kotahi marama o te maimoatanga ki te GC203, i heke te pukupuku mā te 37.3%.
Ngā Whakatau: Te Whakatōnga o GC203he haumaru e whakaaetia ana, ā, he kaha te whai huatanga mō ngā tūroro OC e hokihoki ana, engari he iti noa ngā kōwhiringa maimoatanga.
I tēnei wā, he maha tonu ngā whakamātautau haumanu o ngā hangarau hou hei ārai i te matepukupuku i Haina e rapu ana i ngā tūroro. Mēnā kei te hiahia koe ki te kōrero mō ngā rongoā me ngā hangarau hou, ka taea e koe te whakapā atu ki te Tari Ao o te Hōhipera Oncology Rohe Tonga o Beijing.
Tau Waea：4008803716
Email：myimmnet@163.com
Ngā Tohutoro
1.https://www.juncell.com/academic-achievements
2.https://www.juncell.com/company-news-76
3.https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.5552
4.http://myimm.net/mianyizhiliao/2037.html
Wā tuku: Hakihea-11-2024